首页> 美国卫生研究院文献>Therapeutic Advances in Psychopharmacology >How user knowledge of psychotropic drug withdrawal resulted in the development of person-specific tapering medication
【2h】

How user knowledge of psychotropic drug withdrawal resulted in the development of person-specific tapering medication

机译:用户对精神药物的知识如何提取导致人群特异性逐渐变细药物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Coming off psychotropic drugs can cause physical as well as mental withdrawal, resulting in failed withdrawal attempts and unnecessary long-term drug use. The first reports about withdrawal appeared in the 1950s, but although patients have been complaining about psychotropic withdrawal problems for decades, the first tentative acknowledgement by psychiatry only came in 1997 with the introduction of the ‘antidepressant-discontinuation syndrome’. It was not until 2019 that the UK Royal College of Psychiatrists, for the first time, acknowledged that withdrawal can be severe and persistent. Given the lack of a systematic professional response, over the years, patients who were experiencing withdrawal started to work out practical ways to safely come off medications themselves. This resulted in an experience-based knowledge base about withdrawal which ultimately, in The Netherlands, gave rise to the development of person-specific tapering medication (so-called tapering strips). Tapering medication enables doctors, for the first time, to flexibly prescribe and adapt the medication required for responsible and person-specific tapering, based on shared decision making and in full agreement with recommendations in existing guidelines. Looking back, it is obvious that the simple practical solution of tapering strips could have been introduced much earlier, and that the traditional academic strategy of comparisons from randomised trials is not the logical first step to help individual patients. While randomised controlled trials (RCTs) are the gold standard for evaluating interventions, they are unable to accommodate the heterogeneity of individual responses. Thus, a more individualised approach, building on RCT knowledge, is required. We propose a roadmap for a more productive way forward, in which patients and academic psychiatry work together to improve the recognition and person-specific management of psychotropic drug withdrawal.
机译:脱离精神药物可能导致身体和精神戒断,导致退出尝试失败和不必要的长期药物使用。关于退出的第一份报告出现在20世纪50年代,但虽然患者一直在抱怨青睐的问题几十年来,但精神病学初步致谢仅在1997年引入“抗抑郁症综合征”。直到2019年,英国皇家精神科医生首次承认撤回可能是严重和持久的。鉴于缺乏系统的专业反应,多年来,遇到退出的患者开始锻炼实际的方法来安全地脱离药物。这导致基于经验的知识库关于提取,最终,在荷兰,引起了特异性锥形药物的发展(所谓的锥形条带)。锥度药物首次使医生能够灵活地规定和适应负责任和特定于个人逐方的药物,并根据公共决定和全面协议与现有准则的建议完全一致。回顾一下,很明显,锥形条的简单实际解决方案可能已经介绍了很多,而随机试验的比较的传统学术策略不是帮助个别患者的逻辑第一步。虽然随机对照试验(RCT)是用于评估干预措施的黄金标准,但它们无法适应个体反应的异质性。因此,需要更个性化的方法,建立在RCT知识上。我们提出了一种更富有成效的方式的路线图,其中患者和学术精神病学合作,以改善精神药物戒断的识别和特异性管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号